ARS Pharmaceuticals wins fast track status for epinephrine nasal spray

ARS Pharmaceuticals said this week that it won fast track status from the FDA for its investigational intranasal epinephrine spray, ARS-1.
The San Diego, Calif.-based company’s device is designed to be an easy-to-use treatment for people suffering from severe allergic reactions to food, drugs and insect bites.
Get the full story at our sister site, Drug Delivery Business News.
The post ARS Pharmaceuticals wins fast track status for epinephrine nasal spray appeared first on MassDevice.

Source: Mass Device - February 21, 2019 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Compliance Respiratory arspharmaceuticals Source Type: news